Quick Answer
Tvardi Therapeutics, Inc. reported Operating Income Loss of -$26.75 million for the year ending 2025.
- Tvardi Therapeutics, Inc. showed an increase of +4.8% in Operating Income Loss from 2024 to 2025.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$1.51 million | Q2 2013: $6.92 million | Q3 2013: -$3.54 million | Q1 2014: -$3.42 million | Q2 2014: -$3.71 million | Q3 2014: -$6.60 million | Q1 2015: -$4.72 million | Q2 2015: -$5.73 million | Q3 2015: -$5.01 million | Q1 2016: -$10.99 million | Q2 2016: -$13.33 million | Q3 2016: -$11.77 million | Q1 2017: -$22.33 million | Q2 2017: -$9.63 million | Q3 2017: -$12.96 million | Q1 2018: -$17.12 million | Q2 2018: -$17.81 million | Q3 2018: -$20.47 million | Q1 2019: -$23.13 million | Q2 2019: -$24.14 million | Q3 2019: -$34.43 million | Q1 2020: -$30.00 million | Q2 2020: -$25.88 million | Q3 2020: -$17.02 million | Q1 2021: -$23.56 million | Q2 2021: -$30.88 million | Q3 2021: -$1.12 million | Q1 2022: -$27.91 million | Q2 2022: -$4.47 million | Q3 2022: -$23.85 million | Q1 2023: -$27.65 million | Q2 2023: -$32.34 million | Q3 2023: -$28.90 million | Q1 2024: -$29.67 million | Q2 2024: -$7.18 million | Q3 2024: -$5.68 million | Q1 2025: -$2.39 million | Q2 2025: -$8.87 million | Q3 2025: -$5.94 million.
- Over the full 14 years of available data (2012 to 2025), Tvardi Therapeutics, Inc.'s Operating Income Loss has declined by 328.9%.
- Historical annual values: Fiscal year 2025: -$26.75 million | Fiscal year 2024: -$28.11 million | Fiscal year 2023: -$121.50 million | Fiscal year 2022: -$87.54 million | Fiscal year 2021: -$89.08 million | Fiscal year 2020: $5.39 million | Fiscal year 2019: -$111.68 million | Fiscal year 2018: -$77.38 million | Fiscal year 2017: -$59.49 million | Fiscal year 2016: -$58.40 million | Fiscal year 2015: -$25.19 million | Fiscal year 2014: -$18.07 million | Fiscal year 2013: -$237.0 thousand | Fiscal year 2012: -$6.24 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: